Company intelligence / Profile preview
AmMax Bio
Not specified, California, United Statesammaxbio.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 2
01
Overview
AmMax Bio’s lead asset AMB‑066, a monoclonal antibody targeting CSF1R, has demonstrated a well-established safety profile across six completed clinical trials and is currently in Phase 2a for CRC MRD. The company also has an ADC program in development for AML and potentially solid tumors. Early results indicate strong translational expertise and robust preclinical data supporting further development.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodies (mAbs)Antibody-drug conjugates (ADCs)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Amgen Inc. – exclusive worldwide license to monoclonal antibody targeting CSF1R; minority ownership stake by AmgenMD Anderson Cancer Center – collaboration to develop AMB‑066 for CRC MRD patients
Beyond the preview
Go deeper on AmMax Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AmMax Bio.